CLINICAL_TRIALS trial_result · 2015-01-21

Clinical Trial Update: Safety Study of VM206RY in Subjects With Expression of HER2 in Breast Cancer [Phase 1]

This is a Phase 1 safety study of VM206RY in HER2-expressing breast cancer, which has completed enrollment. The trial status is listed as COMPLETED.

Upgrade for the full analysis, importance score, and drug timeline.

Sponsor: Reyon Pharmaceutical Co., Ltd. | Conditions: Breast Cancer | Phase 1 | Status: COMPLETED